Anixa Biosciences Inc — fact timeline

Anixa Biosciences Inc entered into Joint Development and Option Agreement with Cleveland Clinic Foundation valued at Company will pay CCF a non-refundable, option fee on or before May 23, 2024, and development funding (effective 2024-05-03).

“On May 3, 2024, Anixa Biosciences, Inc. (the “ Company ”) and the Cleveland Clinic Foundation (the “ CCF ”) entered into a Joint Development and Option Agreement (the “ Agreement ”). Pursuant to the Agreement, the parties agreed on the terms and conditions under which the parties will collaborate in efforts to develop vaccines for the prevention or treatment of cancers in the Fields.”

Anixa Biosciences Inc shareholders approved Ratification of the appointment of independent registered public accounting firm at the 2024-03-21 meeting.

“The voting results were as follows: Shares Voted For Shares Voted Against Shares Abstaining Broker Non-Vote 18,390,227 80,392 51,167 -”

Anixa Biosciences Inc shareholders approved Approval, by non-binding advisory vote, of the Company's executive compensation at the 2024-03-21 meeting.

“The voting results were as follows: Votes For Votes Against Abstentions Broker Non-Votes 6,010,385 1,843,353 123,415 10,544,633”

Anixa Biosciences Inc shareholders approved Election of directors at the 2024-03-21 meeting.

“The voting results were as follows: Nominee Shares Voted For Shares Withheld Broker Non-Vote Dr. Amit Kumar 7,894,499 82,654 10,544,633 Dr. Arnold Baskies 7,857,006 120,147 10,544,633 Emily Gottschalk 7,853,085 124,068 10,544,633 Lewis H. Titterton, Jr. 7,718,162 258,991 10,544,633”

Anixa Biosciences Inc shareholders approved Ratification of the appointment of independent registered public accounting firm at the 2023-03-09 meeting.

“Proposal No. 3 – Ratification of the appointment of independent registered public accounting firm The appointment of Haskell & White LLP as the Company’s independent registered public accounting firm for the fiscal year ending October 31, 2023 was ratified. The voting results were as follows: Shares Voted For Shares Voted Against Shares Abstaining Broker Non-Vote 20,439,779 61,616 468,463 -”

Anixa Biosciences Inc shareholders approved Approval, by non-binding advisory vote, of the Company's executive compensation at the 2023-03-09 meeting.

“Proposal No. 2 – Approval, by non-binding advisory vote, of the Company’s executive compensation The Company’s executive compensation, by non-binding advisory vote, was approved. The voting results were as follows: Votes For Votes Against Abstentions Broker Non-Votes 9,166,107 1,816,322 221,564 9,765,865”

Anixa Biosciences Inc shareholders approved Election of directors at the 2023-03-09 meeting.

“Proposal No. 1 – Election of directors Dr. Amit Kumar, Dr. Arnold Baskies, Emily Gottschalk, and Lewis H. Titterton, Jr. were each re-elected to serve until the 2024 annual meeting of stockholders or until their successors are elected and qualified or until their earlier resignation or removal. The voting results were as follows: Nominee Shares Voted For Shares Withheld Broker Non-Vote Dr. Amit Kumar 10,263,393 940,600 9,765,865 Dr. Arnold Baskies 10,273,898 930,095 9,765,865 Emily Gottschalk 10,055,355 1,148,638 9,765,865 Lewis H. Titterton, Jr. 9,825,204 1,378,789 9,765,865”

Amit Kumar changed role as President at Anixa Biosciences Inc.

“Mr. Catelani is replacing Dr. Amit Kumar, the prior President and current Chairman and Chief Executive Officer of the Company.”

Michael Catelani changed role as President at Anixa Biosciences Inc.

“On April 14, 2022, the Board of Directors of Anixa Biosciences, Inc. (“we,” “us,” “our,” or the “Company”) promoted Michael Catelani, the current Chief Operating Officer and Chief Financial Officer of the Company, to President of the Company effective immediately.”